Missed our patient involvement webinar? Recording now available!

Patients are key in the success of patient preference studies. In our webinar on 11 June, we discussed the role of patients as partners in patient preference studies and explained the value of involving patients at the stages of design and while conducting a patient preference study as well as at the level of communication results back to patients after. Now, the recordings are available. 

The recoded webinar is now available on the PREFER YouTube channel. You can watch it in its entirety or scroll to find the parts below. If you want to be invited to future PREFER webinars, sign up for our newsletter! (Link removed)  Or have a look at our event calendar (Link removed)  to find out what has been planned already.

Introducing patient involvement in patient preference studies

In this presentation Isabelle Huys from KU Leuven provides an introduction to patient involvement in patient preference studies. 


Involvement of patients in design of patient preference studies

Eline van Overbeeke from Pfizer talks about how to involve patients in the design of a patient preference study in this presentation. 


Involvement of patients in conduct of patient preference studies

Rosanne Janssens of KU Leuven talks about her experience of involving patients while conducting patient preferences. 


Involvement of patients in communication of patient preference studies

Meredith Smith from Alexion of talks about involving patients in communicating about patient preference studies. 


Short testimony from patients and clinical study leads

Patients and PREFER clinical case study (Link removed) lead Marie Falahee from the University of Birmingham gave testimony about their most relevant experiences and where they believe patient involvement really matters. 


Key lessons from patients

Antonella Cardone from European Cancer Patient Coalition (ECPC) shares key lessons from patients. 






  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).